3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
15
Phase 1
7
Phase 1/2
3
Phase 3
2
Phase NA
1
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Breast Neoplasms
10
Prostatic Neoplasms
6
Multiple Myeloma
5
Neoplasms
3
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Carcinoma, Hepatocellular
3
Papillomavirus Infections
2
Neoplasm Metastasis
2
Melanoma
2
Leiomyoma
2
Carcinoma, Non-Small-Cell Lung
2
Vomiting
1
Venous Thromboembolism
1
Tumor Lysis Syndrome
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thalassemia
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Substitutes
1
Skin Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Post-operative Seroma Formation
1
Polycythemia Vera
1
Parathyroid Diseases
1
Overweight
1
Osteoradionecrosis
1
Opioid-Related Disorders
1
Interventions
nilotinib
1
bosutinib
1
asciminib
1
Imatinib Mesylate
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Myeloproliferative Disorders
×
30 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled